Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Nov 13, 2018 in Prostate cancer | 0 comments

In a nutshell

This study aimed to investigate the safety and effectiveness of stereotactic body radiation therapy (SBRT) as a treatment for prostate cancer. This study found that SBRT is a safe and effective option for low and medium risk prostate cancer.

Some background

Stereotactic body radiotherapy (SBRT) is a treatment option for prostate cancer. SBRT is different from typical radiation therapy treatment. It can be carried out in fewer treatments and is very precise. It delivers a higher dose of radiation per treatment from different directions. A treatment schedule could be 40Gy in 5 treatments. Gy is the unit of measurement for radiation. The long-term safety and effectiveness of SBRT are still unknown.

Methods & findings

This study included 309 patients with prostate cancer treated with SBRT. 172 low-risk and 137 medium-risk patients were treated in 21 centers. They received 40Gy in 5 treatments. Patients were followed up for an average of 61 months. 

95.6% of patients were alive 5 years after treatment. 97.1% of patients were tumor free at 5 years. Low-risk patients had a tumor-free 5-year survival of 97.3%. This rate was 97.1% in the medium-risk group.

Side-effects were mainly minor, including diarrhea and skin soreness. 4 patients experienced more serious side-effects, such as blood in the urine. 

The bottom line

This study found that SBRT is an effective and safe treatment option for low and medium risk prostate cancer.

The fine print

Late side-effects could occur after SBRT. Longer-term follow-up studies are needed.

Published By :

International journal of radiation oncology, biology, physics

Date :

Sep 26, 2018

Original Title :

Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.

click here to get personalized updates